000131599 001__ 131599
000131599 005__ 20240228145608.0
000131599 0247_ $$2doi$$a10.1161/CIRCGENETICS.116.001691
000131599 0247_ $$2pmid$$apmid:29018006
000131599 0247_ $$2ISSN$$a1942-325X
000131599 0247_ $$2ISSN$$a1942-3268
000131599 0247_ $$2altmetric$$aaltmetric:30589220
000131599 037__ $$aDKFZ-2017-06231
000131599 041__ $$aeng
000131599 082__ $$a610
000131599 1001_ $$aOder, Daniel$$b0
000131599 245__ $$aα-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease.
000131599 260__ $$aPhiladelphia, Pa.$$bLippincott, Williams & Wilkins$$c2017
000131599 3367_ $$2DRIVER$$aarticle
000131599 3367_ $$2DataCite$$aOutput Types/Journal article
000131599 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524660098_18426
000131599 3367_ $$2BibTeX$$aARTICLE
000131599 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000131599 3367_ $$00$$2EndNote$$aJournal Article
000131599 500__ $$aHerz-Kreislauf
000131599 520__ $$aHypertrophic cardiomyopathy is the most common type of cardiomyopathy, but many patients lack sarcomeric/myofilament mutations. We studied whether cardio-specific α-galactosidase A gene variants are misinterpreted as hypertrophic cardiomyopathy because of the lack of extracardiac organ involvement.All subjects who tested positive for the N215S genotype (n=26, 13 females, mean age 49±17 [range, 14-74] years) were characterized in this prospective monocentric longitudinal cohort study to determine genotype-specific clinical characteristics of the N215S (c.644A>G [p.Asn215Ser]) α-galactosidase A gene variant. All subjects were initially referred with suspicion of genetically determined hypertrophic cardiomyopathy. Cardiac hypertrophy (interventricular septum, 12±4 [7-23] mm; left ventricular posterior wall, 11±4 [7-21] mm; left ventricular mass, 86±41 [46-195] g/m2) was progressive, systolic function mainly preserved (cardiac index 2.8±0.6 [1.9-3.9] L/min per m2), and diastolic function mildly abnormal. Cardiac magnetic resonance imaging revealed replacement fibrosis in loco typico (18/26, 69%), particularly in subjects >50 years. Elderly subjects had advanced heart failure, and 6 (23%) were suggested for implantable cardioverter-defibrillator therapy. Leukocyte α-galactosidase A enzyme activity was mildly reduced in 19 subjects and lyso-globotriaosylceramide slightly elevated (median, 4.9; interquartile range, 1.3-9.1 ng/mL). Neurological and renal impairments (serum creatinine, 0.87±0.20; median, 0.80; interquartile range, 0.70-1.01 mg/dL; glomerular filtration rate, 102±23; median, 106; interquartile range, 84-113 mL/min) were discreet. Only 2 subjects developed clinically relevant proteinuria.α-Galactosidase A genotype N215S does not lead to the development of a classical Fabry phenotype but induces a specific cardiac variant of Fabry disease mimicking nonobstructive hypertrophic cardiomyopathy. The lack of prominent noncardiac impairment leads to a significant delay in diagnosis and Fabry-specific therapy.
000131599 536__ $$0G:(DE-HGF)POF3-322$$a322 - Genetics and Pathophysiology (POF3-322)$$cPOF3-322$$fPOF III$$x0
000131599 588__ $$aDataset connected to CrossRef, PubMed,
000131599 7001_ $$aLiu, Dan$$b1
000131599 7001_ $$aHu, Kai$$b2
000131599 7001_ $$aÜçeyler, Nurcan$$b3
000131599 7001_ $$aSalinger, Tim$$b4
000131599 7001_ $$aMüntze, Jonas$$b5
000131599 7001_ $$aLorenz, Kristina$$b6
000131599 7001_ $$aKandolf, Reinhard$$b7
000131599 7001_ $$0P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91$$aGröne, Hermann-Josef$$b8$$udkfz
000131599 7001_ $$aSommer, Claudia$$b9
000131599 7001_ $$aErtl, Georg$$b10
000131599 7001_ $$aWanner, Christoph$$b11
000131599 7001_ $$aNordbeck, Peter$$b12
000131599 773__ $$0PERI:(DE-600)2457085-0$$a10.1161/CIRCGENETICS.116.001691$$gVol. 10, no. 5, p. e001691 -$$n5$$pe001691 -$$tCirculation / Cardiovascular genetics$$v10$$x1942-3268$$y2017
000131599 909CO $$ooai:inrepo02.dkfz.de:131599$$pVDB
000131599 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000131599 9131_ $$0G:(DE-HGF)POF3-322$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vGenetics and Pathophysiology$$x0
000131599 9141_ $$y2017
000131599 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCIRC-CARDIOVASC GENE : 2015
000131599 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000131599 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000131599 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000131599 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000131599 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000131599 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000131599 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000131599 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000131599 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000131599 9201_ $$0I:(DE-He78)G130-20160331$$kG130$$lZelluläre und Molekulare Pathologie$$x0
000131599 980__ $$ajournal
000131599 980__ $$aVDB
000131599 980__ $$aI:(DE-He78)G130-20160331
000131599 980__ $$aUNRESTRICTED